Thursday, April 08, 2010 10:26:04 PM
FDA NVS June 2010--Gilenia for multiple sclerosis
July $60 .05/.15 with 9693 open interest (largest)
Novartis (NVS)
Drug/indication: Gilenia for multiple sclerosis
Approval decision date: June 2010 (Novartis has not disclosed the exact date.)
The FDA is holding an advisory committee meeting on June 10 to review Gilenia. If approved, Gilenia would be the first multiple sclerosis drug administered as a pill, and as such, the drug could have an impact on already approved, injectable MS drugs from Biogen Idec(BIIB), Teva(TEVA) and Merck-Serono.
July $60 .05/.15 with 9693 open interest (largest)
Novartis (NVS)
Drug/indication: Gilenia for multiple sclerosis
Approval decision date: June 2010 (Novartis has not disclosed the exact date.)
The FDA is holding an advisory committee meeting on June 10 to review Gilenia. If approved, Gilenia would be the first multiple sclerosis drug administered as a pill, and as such, the drug could have an impact on already approved, injectable MS drugs from Biogen Idec(BIIB), Teva(TEVA) and Merck-Serono.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
